Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Amdocs Director Adrian Gardner Buys $215K of Stock
Adrian Gardner, Director, bought 5,000 shares of Amdocs Ltd at $43.02 a share, worth $215K in total on Nov 12, 2026. Shares held after the trade: 25,000 (+25.0%).
Connect Biopharma received a deficiency notice from Nasdaq on November 12, 2026, because its ordinary shares closed below the $1.00 minimum bid price requirement for 30 consecutive business days. The company has until May 11, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for at least ten consecutive business days. The notice has no immediate effect on the listing of the company's shares, which continue to trade under the symbol 'CNTB'.
Counterparty
Nasdaq
Term
180 days
“We believe topline results from our Phase 2 Seabreeze STAT asthma and COPD studies mark a significant inflection point in the development of rademikibart as an add-on treatment to rescue bronchodilators and systemic corticosteroids for the treatment of acute exacerbations.”
Barry Quart, Pharm.D., CEO and Director of Connect Biopharma
“We believe these findings support the potential of rademikibart to redefine how acute exacerbations are managed, addressing both the acute event and the 4-week high-risk period following an exacerbation, to improve patient outcomes and reduce the substantial economic burden on healthcare systems.”
Barry Quart, Pharm.D., CEO and Director of Connect Biopharma
CervoMed presented 24-week interim biomarker data from its Phase 2a trial of neflamapimod in patients with nonfluent variant primary progressive aphasia (nfvPPA). The data showed an exposure-dependent reduction in neurofilament light chain (NfL), a key biomarker of neuronal damage, in patients with higher plasma drug levels. Full 24-week biomarker and clinical data from the study are expected in the first quarter of 2027.
Rapid Micro Biosystems M&A Deal with Merck KGaA, Darmstadt, Germany
Rapid Micro Biosystems has entered into a definitive merger agreement to be acquired by Merck KGaA, Darmstadt, Germany for $0.75 per share in an all-cash tender offer. Following the transaction, which is expected to close in December 2026, Rapid Micro Biosystems will become a wholly owned subsidiary of Merck KGaA's Life Science business. The deal aims to expand the reach of the Growth Direct platform for automated microbial quality control in pharmaceutical manufacturing.
BrainStorm Cell Therapeutics reported financial results for the third quarter ended September 30, 2026, and provided a corporate update on its Phase 3b ENDURANCE study of NurOwn in ALS. The company highlighted the appointment of former FDA official Professor Peter J. Pitts as Executive Chairman to lead regulatory and capital-markets initiatives. Net loss for the quarter was $2.1 million, or $0.03 per share, as the company prepares for the initiation of its next clinical trial phase.
Term
Q3 2026
“ALS remains a devastating disease with a critical unmet medical need, and patients urgently need new therapeutic options. We continue to advance and complete the preparations necessary to initiate the Phase 3b ENDURANCE study of NurOwn® in ALS, supported by an FDA-agreed protocol under a Special Protocol Assessment.”
Chaim Lebovits, President and Chief Executive Officer
Aqua Metals reported third quarter 2026 financial results, highlighting a 19% year-over-year reduction in operating expenses. The company established offtake pathways via letters of intent for all three primary product streams at its Project Headwaters ARC facility, including copper, aluminum, and lithium carbonate.
“The third quarter was about converting commercial discussions into agreements and lowering the cost of carrying the business while we advance the funding strategy for Project Headwaters ARC.”
Steve Cotton, President and Chief Executive Officer
“We end the quarter with offtake pathways across all three primary product streams, a better-defined Phase 1 project and a lower cost base. Each of those puts Aqua Metals in a better position to act as funding and policy conditions become clearer.”
Steve Cotton, President and Chief Executive Officer
Mid-America Apartment Communities (MAA) filed a formal investor presentation deck to be used at the Nareit REITworld conference from November 17-19, 2026. The presentation provides strategic highlights and operational updates for the multifamily REIT. The filing was made under Item 7.01 of Form 8-K to comply with Regulation FD.
Guardant Health $550M Debt Financing with U.S. Bank Trust Company, National Association
Guardant Health completed a private offering of $550 million in 0% Convertible Senior Notes due 2032, which included the full exercise of the initial purchasers' option for an additional $50 million. The notes feature an initial conversion price of approximately $208.95 per share, representing a 35% premium over the November 11, 2026 closing price. Proceeds will be used to repurchase a portion of the company's existing 2027 convertible notes, fund capped call transactions, and for general corporate purposes.
MetLife, Inc. declared quarterly cash dividends on its Series A, Series E, and Series F non-cumulative preferred stock. The dividends are payable on December 15, 2026, to shareholders of record as of November 30, 2026.
Cumberland Pharmaceuticals announced top-line results from its Phase 2a ASSIST-SSc trial evaluating oral ifetroban in patients with systemic sclerosis (SSc). The study met its primary objective of demonstrating that ifetroban was generally well tolerated with a safety profile consistent with prior experience, though the trial was not powered to detect significant efficacy differences due to limited disease progression in both groups.
InPoint Commercial Real Estate Income Business Update
InPoint Commercial Real Estate Income, Inc. announced its monthly Net Asset Value (NAV) per share as of October 31, 2026. The aggregate NAV per share was determined to be $13.4472, with total net asset value attributable to common stock of approximately $136.1 million.
FB Financial Corporation made available an investor presentation for use by management during various conferences in the fourth quarter of 2026. The presentation provides a strategic overview of the company's business segments, including its banking and mortgage operations.
Western Digital $1.5B Debt Financing with Bank of America, N.A.
Western Digital entered into a new $1.5 billion senior unsecured revolving credit facility maturing in 2031, replacing its existing 2022 loan agreement. The new facility features a $200 million sublimit for letters of credit and interest rates based on the company's credit ratings. The agreement includes a maximum leverage ratio covenant of 3.25 to 1.00, which can be temporarily increased following material acquisitions.
Cumberland Pharmaceuticals announced plans to submit a New Drug Application (NDA) to the FDA for ifetroban to treat cardiomyopathy associated with Duchenne muscular dystrophy (DMD). The FDA has granted a rolling submission for the application, which will use data from the FIGHT DMD trial compared against natural history databases. The decision to file follows several regulatory meetings where the company addressed FDA questions regarding Phase 2 study results and efficacy endpoints.
AEON Biopharma reported Q3 2026 financial results and provided a regulatory update on its ABP-450 biosimilar program. The company received FDA Type 2b feedback clarifying its development strategy and submitted an IND for a comparative pharmacodynamic study planned for Q1 2027.
Term
Q3 2026
“Over the past several months, we have made important progress in advancing the scientific and regulatory foundation for ABP-450’s development as a biosimilar to BOTOX®.”
Rob Bancroft, President and Chief Executive Officer
“With our CMAP IND submitted and additional capital secured through the recent milestone warrant exercises, we are positioned to advance the next phase of development, including the planned initiation of our comparative pharmacodynamic study in the first quarter of 2027.”
Rob Bancroft, President and Chief Executive Officer
Stem, Inc. announced that Saul Laureles, Chief Legal Officer and Secretary, will leave the company effective November 24, 2026. The Board has appointed Jessica Palomino, the company's current Vice President and Senior Counsel – Operations, to succeed him as Chief Legal Officer and Secretary on the same date. Mr. Laureles will remain as a non-executive advisor through December 13, 2026, to ensure an orderly transition.
Dave Inc. has filed applications with the OCC and FDIC to establish Dave Bank, N.A. as a full-service national bank and wholly-owned subsidiary. The company also intends to apply to the Federal Reserve to become a bank holding company, a move intended to allow Dave to offer deposit and credit products directly under federal supervision. In connection with the application, Anthony Sharett has been appointed as Chief Banking Officer and proposed President of the Bank.
Jacobs Solutions Inc. has appointed Richard D. Phillips to its Board of Directors, effective December 1, 2026, increasing the board size to 10 members. Phillips, currently the CEO of Kimball Electronics and a former McKinsey partner, will receive a $135,000 annual cash retainer and a pro-rated $200,000 annual RSU award. The appointment adds significant public company leadership and strategic advisory experience to the board as the company executes its long-term strategy.
Sun Communities, Inc. filed a formal investor presentation deck (Exhibit 99.1) to be used for investor meetings beginning November 16, 2026. The presentation provides strategic highlights and operational updates following the company's completed sale of its Park Holidays business unit.
Aytu Biopharma Signs $56M M&A Deal with Rosemont Pharmaceuticals Holdings, Inc.
Aytu BioPharma has entered into a definitive agreement to be acquired by Rosemont Pharmaceuticals Holdings, Inc. for $2.70 per share in cash, representing a total deal value of approximately $56 million. The transaction will be structured as a cash tender offer followed by a merger and is expected to close by the end of calendar 2026. The company also reported Q1 fiscal 2027 revenue of $14.8 million alongside the merger announcement.
Value
$56M
Counterparty
Rosemont Pharmaceuticals Holdings, Inc.
“Today, we announced that Aytu has entered into a definitive agreement to be acquired by Rosemont for $2.70 per share in cash. This agreement with Rosemont reflects the work our team has done to build our CNS and pediatric portfolio and earn the trust of the patients and healthcare providers we serve.”
Josh Disbrow, Chief Executive Officer of Aytu
“Importantly, we believe the transaction delivers compelling value to our shareholders and that, together, we can help more patients get the treatment they need.”
Blue Dolphin Energy Company reported Q3 2026 net income of $18.9 million, a significant turnaround from a net loss of $4.7 million in the prior year period. The company saw strong operational performance in its refinery segment, generating $23.9 million in refinery operations EBITDA for the quarter. Cash and cash equivalents improved to $40.8 million as of September 30, 2026, driven by $54.4 million in operating cash flow year-to-date.
Term
Q3 2026
“Blue Dolphin delivered another quarter of strong operational and financial performance by capitalizing on market opportunities. We remain focused on safe, reliable operations, margin capture, capital discipline, and value creation while enhancing refining capacity and capabilities.”
Jonathan P. Carroll, Chief Executive Officer of Blue Dolphin Energy Company
Neighborhood Intelligence, Inc. announced that its Board of Directors has authorized a new share repurchase program to buy back up to $25 million of its outstanding common stock. The program allows for repurchases through open market or private transactions and has no fixed expiration date. This move signals management's commitment to returning capital to shareholders and confidence in the company's valuation.
Firy Inc. reported Q3 2026 revenue of $31.3 million, a 14% year-over-year increase, driven by 141% growth in its RZR segment. The company narrowed its net loss to $12.5 million and reached a debt-free status following the redemption of $49.7 million in senior secured notes in October. Management highlighted progress in collecting a $730 million judgment against Papaya Gaming and expects positive operating cash flow in 2027.
Term
Q3 2026
“We made substantial progress in Q3 2026, with strong execution across the organization driving accelerating momentum in our transition from turnaround to growth. Revenue grew 14% year over year, led by RZR, which grew 141% and for the first time made up the majority of quarterly revenue.”
Andrew Paradise, FIRY CEO
“Our third quarter results highlight the operating leverage in our business. Our net loss narrowed by $4.9 million year over year, and Adjusted EBITDA excluding litigation expense was a loss of $1.2 million, a $6.2 million improvement from a year ago.”
Diversified Healthcare Trust (DHC) filed a formal investor presentation for the NAREIT conference in November 2026. The presentation covers the company's 2026 guidance, senior housing operating portfolio (SHOP) optimization strategy, and strategic capital recycling plans. The filing is intended to provide updates on DHC's balance sheet improvements and asset management strategies to the investment community.
FutureFuel Insider Ronald J. Kruszewski Buys $284K of Stock
Ronald J. Kruszewski bought 100,000 shares of FutureFuel Corp. at $2.84 a share, worth $284K in total on Nov 12, 2026. Shares held after the trade: 110,000 (+1000.0%).
e.l.f. Beauty appointed Amit Khetan, the company's current Chief Accounting Officer, to the additional role of principal accounting officer effective November 12, 2026. He succeeds Mandy Fields in this capacity, who will continue to serve as the company's Senior Vice President and Chief Financial Officer. Mr. Khetan will not receive any additional compensation in connection with this appointment.
Research Solutions reported its first quarter fiscal year 2027 results, highlighted by an 11.5% year-over-year increase in B2B Annual Recurring Revenue (ARR) to $16.5 million. While total revenue slightly decreased to $11.9 million due to lower transaction volume, gross margins improved by 300 basis points to 53.6% as the company continues its strategic shift toward higher-margin platform subscription revenue.
Term
Q1 2027
“Our continued investment in innovation is expanding how researchers discover, access, and engage with scientific literature. Recent launches of Article Galaxy and Scite integrations with ChatGPT, Claude, and Microsoft Copilot bring our capabilities directly into the AI-powered workflows researchers increasingly rely on, making it easier to find trusted evidence and access scholarly content.”
Roy W. Olivier, President and CEO
“Platform revenue accounted for 45% of total revenue this quarter, up from 42% a year ago, reflecting our continued transition toward a higher-margin, recurring revenue model. This evolution is strengthening profitability and operating cash flow, enabling us to reinvest in sales capacity and product innovation to accelerate long-term growth.”
LifeStance Health Group Insider TPG Gp a LLC Sells $485M of Stock
TPG Gp a LLC sold 37,233,110 shares of LifeStance Health Group, Inc. at $13.02 a share, worth $485M in total on Nov 12, 2026. Shares held after the trade: 42,458,592 (-46.7%).
Merck & Co EVP&Pres, Merck Animal Heallth Richard R. DeLuca Sells $8.61M of Stock
Richard R. DeLuca, EVP&Pres, Merck Animal Heallth, sold 58,185 shares of Merck & Co., Inc. at $148.01 a share, worth $8.61M in total on Nov 12, 2026. Shares held after the trade: 112,955 (-34.0%).
CV Sciences Insider Charlie E. Cheever III Buys $45.6K of Stock
Charlie E. Cheever III bought 4,557,721 shares of CV Sciences, Inc. at $0.01 a share, worth $45.6K in total between Nov 4, 2026 and Nov 9, 2026. Shares held after the trade: 31,706,432 (+6.7%).